Table 3 Comparison of studied KIR activating genes and some disease characteristics in AIH-I patients
| Â | KIR2DS1 | KIR2DS4 | ||||
|---|---|---|---|---|---|---|
+ (N = 68) | − (N = 12) | P | + (N = 74) | − (N = 6) | P | |
Anti-nuclear antibodies (ANA) | ||||||
 Negative | 52 (76.5) | 12 (100) | 0.32 | 64 (86.5) | 0 | < 0.001 |
 Positive | 16 (23.5) | 0 | 10 (13.5) | 6 (100) | ||
Anti-smooth muscle antibodies (ASMA) | ||||||
 Negative | 10 (14.7) | 2 (16.7) | 1.00 | 12 (16.2) | 0 | 1.00 |
 Positive | 58 (85.3) | 10 (83.3) | 62 (83.8) | 6 (100) | ||
Treatment regimen | ||||||
 Steroid | 22 (32.3) | 4.(33.3) | 1.00 | 20 (27) | 6 (100) | 0.008 |
 Steroid and azathioprine | 46 (67.7) | 8 (66.7) | 54 (73) | 0 | ||
Treatment response | ||||||
 Complete remission | 40 (58.8) | 6 (50) | 1.00 | 40 (54) | 6 (100) | 0.036 |
 Relapse | 28 (41.2) | 6 (50) | 34 (46) | 0 | ||
Hepatitis Activity Index (HAI) | ||||||
|  | 7.06 ± 2.89 | 9.83 ± 4.44 | 0.006 | 7.22 ± 3.21 | 10.67 ± 2.31 | 0.012 |
Degree of fibrosis | ||||||
|  | 2.94 ± 1.01 | 2.67 ± 0.52 | 0.369 | 2.84 ± 0.9 | 3.67 ± 1.53 | 0.043 |